What is the recommended treatment for H pylori (Helicobacter pylori) infection?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: October 24, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Recommended Treatment for Helicobacter pylori Infection

Bismuth quadruple therapy for 14 days is the most effective first-line treatment for H. pylori infection due to increasing global clarithromycin resistance. 1, 2, 3

First-Line Treatment Options

  • Bismuth quadruple therapy (14 days): PPI (twice daily) + bismuth subsalicylate + tetracycline HCl + metronidazole 1, 2, 3

  • In areas with low clarithromycin resistance (<15%): Triple therapy with PPI (twice daily) + clarithromycin 500mg BID + amoxicillin 1g BID for 14 days may be considered 2, 3

  • Concomitant (non-bismuth quadruple) therapy: PPI + clarithromycin + amoxicillin + metronidazole for 14 days is another first-line alternative 2, 3

Optimizing Treatment Success

  • Use high-dose PPI (twice daily) to increase eradication efficacy by 6-10% by reducing gastric acidity and enhancing antibiotic activity 1, 2, 3

  • Extend treatment duration to 14 days to improve eradication success by approximately 5% compared to shorter regimens 4, 1, 2

  • For amoxicillin-containing regimens, administer at the start of a meal to minimize gastrointestinal intolerance 5

Second-Line Treatment Options

  • After failure of clarithromycin-containing therapy, either bismuth quadruple therapy (if not previously used) or levofloxacin-containing triple therapy is recommended 4, 2

  • Levofloxacin-based triple therapy consists of PPI (twice daily) + amoxicillin 1000mg BID + levofloxacin 500mg daily or 250mg BID for 14 days 2, 3

  • Rising rates of levofloxacin resistance should be considered when selecting this option 4, 2

Third-Line and Rescue Therapies

  • After two failed eradication attempts, antimicrobial susceptibility testing should guide further treatment whenever possible 1, 2, 3

  • Rifabutin triple therapy (PPI + amoxicillin + rifabutin) for 14 days is effective for persistent infection, particularly after previous treatment failures 1, 3

  • Rifabutin has the advantage of rare bacterial resistance, making it valuable for persistent infections 1, 3

Verification of Eradication

  • Confirm eradication with urea breath test or monoclonal stool antigen test at least 4 weeks after completion of therapy and at least 2 weeks after PPI discontinuation 1, 2

  • Serology should not be used to confirm eradication as antibodies may persist long after successful treatment 1, 2

Common Pitfalls and Caveats

  • Inadequate PPI dosing significantly reduces H. pylori treatment efficacy; always use high-dose (twice daily) PPI 1, 2

  • Clarithromycin resistance is increasing globally, making traditional triple therapy less effective in many regions 2, 3, 6

  • Avoid repeating antibiotics to which the patient has been previously exposed, especially clarithromycin and levofloxacin 1, 2, 3

  • Bismuth is valuable because bacterial resistance to this compound is extremely rare, making bismuth quadruple therapy effective even against strains resistant to metronidazole 1, 2, 3

  • For patients allergic to penicillin, amoxicillin can be replaced with tetracycline 2

References

Guideline

Treatment for Persistent Helicobacter pylori Infection

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Guideline

Helicobacter pylori Treatment Guidelines

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Guideline

Helicobacter Pylori Infection Treatment Guidelines

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Research

Management of Helicobacter pylori infection.

JGH open : an open access journal of gastroenterology and hepatology, 2023

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.